Lighthouse Pharmaceuticals Secures $12 Million Series A Funding to Fuel Alzheimer's Drug Development
Lighthouse Pharmaceuticals, a California-based biopharmaceutical firm focused on developing innovative small-molecule therapies, has announced the successful closure of a $12 million Series A financing round. This funding was spearheaded by Double Point Ventures, complemented by investments from both freshly recruited and longstanding investors. The capital raised will primarily support the advancement of Lighthouse's leading clinical program, known as LHP588, in addition to fostering the expansion of its research pipeline.
The company is presently engaged in the SPRING clinical trial, which is a Phase 2 study assessing the efficacy of LHP588 in patients with mild to moderate Alzheimer's disease, specifically those who are positive for the P. gingivalis bacterium. Notably, this trial is further bolstered by a significant grant of $49.2 million from the National Institute on Aging (NIA), a branch of the National Institutes of Health (NIH).
Casey Lynch, the CEO of Lighthouse Pharmaceuticals, emphasized the importance of this financing by stating, "Lighthouse is advancing a differentiated approach based on compelling scientific and clinical data. This financing, together with the support from the NIA, gives Lighthouse the resources to efficiently execute the SPRING trial and advance LHP588 toward late-stage development." Lynch highlighted the goal of targeting a specific subset of Alzheimer's patients to refine treatment strategies and improve therapeutic outcomes.
In conjunction with this funding, Dr. Campbell Murray, a partner at Double Point Ventures, will be joining the board of directors at Lighthouse Pharmaceuticals. Dr. Murray's extensive experience in life sciences investing and clinical-stage development is expected to further enhance the company’s strategic direction. Murray voiced his confidence in the potential of Lighthouse’s focused approach, stating, "With LHP588, the company is targeting an important and underexplored biological driver in a defined patient population. We believe the SPRING trial has the potential to generate clinically meaningful data and to further establish Lighthouse as an innovative company in neurodegeneration."
The SPRING trial itself is a double-blind, placebo-controlled study that seeks to evaluate LHP588, which is administered orally once daily. This small-molecule therapy specifically targets P. gingivalis, a bacterium noted for its association with periodontal disease and its emerging role in the onset and advancement of Alzheimer’s disease. Currently, the trial is actively enrolling participants from various locations across the United States, with hopes to gather significant data by its completion. More information about the clinical trial can be found at www.springclinicaltrial.com.
About Lighthouse Pharmaceuticals:
Founded with the mission to address critical healthcare needs, Lighthouse Pharmaceuticals focuses on the development of novel therapeutics aimed at chronic neurodegenerative and inflammatory conditions. The company’s flagship clinical initiative revolves around Alzheimer's disease, including the ongoing SPRING clinical trial examining LHP588’s effectiveness. For further details, visit www.lighthousepharma.com.
The research highlighted in this announcement is supported by the National Institute on Aging from the National Institutes of Health. The viewpoints expressed in this document do not necessarily reflect those of the NIH.
The company is presently engaged in the SPRING clinical trial, which is a Phase 2 study assessing the efficacy of LHP588 in patients with mild to moderate Alzheimer's disease, specifically those who are positive for the P. gingivalis bacterium. Notably, this trial is further bolstered by a significant grant of $49.2 million from the National Institute on Aging (NIA), a branch of the National Institutes of Health (NIH).
Casey Lynch, the CEO of Lighthouse Pharmaceuticals, emphasized the importance of this financing by stating, "Lighthouse is advancing a differentiated approach based on compelling scientific and clinical data. This financing, together with the support from the NIA, gives Lighthouse the resources to efficiently execute the SPRING trial and advance LHP588 toward late-stage development." Lynch highlighted the goal of targeting a specific subset of Alzheimer's patients to refine treatment strategies and improve therapeutic outcomes.
In conjunction with this funding, Dr. Campbell Murray, a partner at Double Point Ventures, will be joining the board of directors at Lighthouse Pharmaceuticals. Dr. Murray's extensive experience in life sciences investing and clinical-stage development is expected to further enhance the company’s strategic direction. Murray voiced his confidence in the potential of Lighthouse’s focused approach, stating, "With LHP588, the company is targeting an important and underexplored biological driver in a defined patient population. We believe the SPRING trial has the potential to generate clinically meaningful data and to further establish Lighthouse as an innovative company in neurodegeneration."
The SPRING trial itself is a double-blind, placebo-controlled study that seeks to evaluate LHP588, which is administered orally once daily. This small-molecule therapy specifically targets P. gingivalis, a bacterium noted for its association with periodontal disease and its emerging role in the onset and advancement of Alzheimer’s disease. Currently, the trial is actively enrolling participants from various locations across the United States, with hopes to gather significant data by its completion. More information about the clinical trial can be found at www.springclinicaltrial.com.
About Lighthouse Pharmaceuticals:
Founded with the mission to address critical healthcare needs, Lighthouse Pharmaceuticals focuses on the development of novel therapeutics aimed at chronic neurodegenerative and inflammatory conditions. The company’s flagship clinical initiative revolves around Alzheimer's disease, including the ongoing SPRING clinical trial examining LHP588’s effectiveness. For further details, visit www.lighthousepharma.com.
The research highlighted in this announcement is supported by the National Institute on Aging from the National Institutes of Health. The viewpoints expressed in this document do not necessarily reflect those of the NIH.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.